ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

Leon Caly; Julian D. Druce; Mike G. Catton; David A. Jans; Kylie M. Wagstaff*
Antiviral Research2020-6-1DOI: 10.1016/j.antiviral.2020.104787
23阅读
引用收藏
分享

摘要

Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.

被引文献 (1)相关
加载中…
  • The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness
    Craig M., Coopersmith; Massimo, Antonelli; Seth R., Bauer; Clifford S., Deutschman; Laura E., Evans; Ricard, Ferrer; Judith, Hellman; Sameer, Jog; Jozef, Kesecioglu; Niranjan, Kissoon; Ignacio, Martin-Loeches; Mark E., Nunnally; Hallie C., Prescott; Andrew, Rhodes; Daniel, Talmor; Pierre, Tissieres; Daniel, De BackerCritical Care Medicine, 2021, 49(4): 598-622.

发表信息

论文状态
公开发表
期刊
Antiviral Research
发表日期
2020-06-01
卷期
第 178 卷
页码
104787
DOI
10.1016/j.antiviral.2020.104787
语言
ENGLISH
期刊收录
NSL.SCIE
期刊等级
2区
成果收录
SCIENCEDIRECT

作者

  • L

    Leon Caly (第一作者)

  • J

    Julian D. Druce

查看全部 5 位作者收起作者
  • M

    Mike G. Catton

  • D

    David A. Jans

  • K

    Kylie M. Wagstaff (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417